A Novel Germline Frameshift Variant in the Tumor Suppressor Gene OBSCN in a Melanoma Patient
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms262110553 ↗Kurz gefasst
Fallbericht in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Barbara Anna Bokor und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Genetics, University of Szeged, 6720 Szeged, Hungary. Hauptthemen laut MEDLINE: Melanoma, Germ-Line Mutation, Frameshift Mutation, Skin Neoplasms. Die Arbeit nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Government of Hungary, Hungarian Government.
Abstract (Originalsprache)
Malignant melanoma is a complex malignancy with genetic, environmental, and lifestyle factors in its etiology. While germline variants in melanoma predisposition genes have been described, many patients remain genetically unexplained after panel testing. We previously analyzed a Hungarian melanoma cohort (n = 17), identifying variants in predisposing or susceptibility genes in 58.82% of patients. For individuals negative on this melanoma-specific panel, we expanded testing to a 19-gene panel associated with multiple cancer types. Next-generation sequencing was performed, followed by Sanger sequencing for confirmation. Variants were classified according to ACMG guidelines. In a 58-year-old female patient with a history of primary cutaneous melanoma, we identified a novel heterozygous frameshift variant in the tumor suppressor gene OBSCN (c.21322_21323insCTGG, p.G7108AfsTer10; NM_001386125.1). This insertion introduces a premature stop codon in exon 89 within the immunoglobulin-like domain, predicting protein truncation. Classified as likely pathogenic (PVS1, PM2), the variant is absent from population databases. To date, somatic OBSCN mutations have been reported in melanoma. This first report of a germline OBSCN frameshift variant in melanoma expands the genetic landscape of melanoma predisposition and suggests that OBSCN may represent a candidate gene contributing to melanoma risk.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Genetics, University of Szeged, 6720 Szeged, Hungary.
- HUN-REN-SZTE Functional Clinical Genetics Research Group, University of Szeged, 6720 Szeged, Hungary.
- Mór Kaposi Teaching Hospital, 7400 Kaposvár, Hungary.
ORCID-Profile: Barbara Anna Bokor, Margit Pál, Zita Battyani, Márta Széll, Nikoletta Nagy
Förderung
- Government of Hungary
- Hungarian Government
Zitieren
APA
Bokor, B. A., Abdolreza, A., Pál, M., Battyani, Z., Széll, M., & Nagy, N. (2025). A Novel Germline Frameshift Variant in the Tumor Suppressor Gene OBSCN in a Melanoma Patient. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms262110553
Vancouver
Bokor BA, Abdolreza A, Pál M, Battyani Z, Széll M, Nagy N. A Novel Germline Frameshift Variant in the Tumor Suppressor Gene OBSCN in a Melanoma Patient. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms262110553
BibTeX
@article{Bokor2025,
author = {Bokor, Barbara Anna and Abdolreza, Aliasgari and Pál, Margit and Battyani, Zita and Széll, Márta and Nagy, Nikoletta},
title = {A Novel Germline Frameshift Variant in the Tumor Suppressor Gene OBSCN in a Melanoma Patient},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms262110553}
}
EUVIMED